The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory Syndrome: A Preliminary Study
Abstract
CONTEXT: Severe acute respiratory syndrome (SARS) is a new clinical entity for which no effective therapeutic strategy has been developed. OBJECTIVE: To provide preliminary results on the potential therapeutic benefit and tolerability of interferon alfacon-1 plus corticosteroids for SARS. DESIGN, SETTING, AND PATIENTS: Open-label study of 22 patients diagnosed as having probable SARS at North York General Hospital, Toronto, Ontario, between April 11 and May 30, 2003. INTERVENTIONS: Thirteen patients were treated with corticosteroids alone and 9 patients were treated with corticosteroids plus subcutaneous interferon alfacon-1. MAIN OUTCOME MEASURES: Clinical parameters, including oxygen saturation and requirement, laboratory measures, and serial chest radiography results. RESULTS: Resolution of fever and lymphopenia were similar between the 2 treatment groups. Of the 13 patients treated with corticosteroids alone, 5 (38.5%) were transferred to the intensive care unit, 3 (23.1%) required intubation and mechanical ventilation, and 1 (7.7%) died. Of the 9 patients in the interferon alfacon-1 treatment group, 3 (33.3%) were transferred to the intensive care unit, 1 (11.1%) required intubation and mechanical ventilation, and none died. The interferon alfacon-1 treatment group had a shorter time to 50% resolution of lung radiographic abnormalities (median time, 4 days vs 9 days; P =.001), had better oxygen saturation (P =.02), resolved their need for supplemental oxygen more rapidly (median, 10 days vs 16 days; P =.02), had less of an increase in creatine kinase levels (P =.03), and showed a trend toward more rapid resolution of lactate dehydrogenase levels compared with the group receiving corticosteroids alone. CONCLUSIONS: In this preliminary, uncontrolled study of patients with SARS, use of interferon alfacon-1 plus corticosteroids was associated with reduced disease-associated impaired oxygen saturation, more rapid resolution of radiographic lung abnormalities, and lower levels of creatine kinase. These findings suggest that further investigation may be warranted to determine the role of interferon alfacon-1 as a therapeutic agent for the treatment of SARS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong
Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G. M., Ahuja, A., Yung, M. Y., Leung, C. B., To, K. F., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030685 · Cited by 2,628
Peiris, J., Chu, C., Cheng, V., Chan, K., Hung, I., Poon, L., Law, K., Tang, B., Hon, T., Chan, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13412-5 · Cited by 2,375
Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area
Booth, C. M. (2003) · JAMA · doi:10.1001/jama.289.21.joc30885 · Cited by 1,406
Identification of Severe Acute Respiratory Syndrome in Canada
Poutanen, S. M., Low, D. E., Henry, B., Finkelstein, S., Rose, D., Green, K., Tellier, R., Draker, R., Adachi, D., Ayers, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030634 · Cited by 1,132
The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion
Levy, D. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00027-7 · Cited by 428 · cited 1×
“Lung involvement, % 20 (5-70) 20 (10-75) .”
Development of a standard treatment protocol for severe acute respiratory syndrome
So, L. K.-Y., Lau, A. C., Yam, L. Y., Cheung, T. M., Poon, E., Yung, R. W., & Yuen, K. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13265-5 · Cited by 317
Epidemiology in public health practice
(2010) · Wageningen Academic Publishers eBooks · doi:10.3920/978-90-8686-140-8 · Cited by 285
Clinical course and management of SARS in health care workers in Toronto: a case series.
Avendaño, M. A., Derkach, P., & Swan, S. (2003) · Europe PMC (PubMed Central) · Cited by 99
A hospital outbreak of severe acute respiratory syndrome in Guangzhou, China.
Wu, W., Wang, J., Liu, P., et al. (2003) · PubMed · Cited by 41
Therapeutic advances in the management of hepatitis B and hepatitis C
Nguyen, M. H., & Wright, T. L. (2001) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200110000-00014 · Cited by 14
Hepatitis C: therapeutic perspectives.
Cornberg, M., Wedemeyer, H. H., & Manns, M. P. (2002) · PubMed · Cited by 14
Cited by
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
Rogers, J. P., Chesney, E., Oliver, D., Pollak, T. A., McGuire, P., Fusar-Poli, P., Zandi, M. S., Lewis, G., & David, A. S. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30203-0 · Cited by 2,407
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
Potential interventions for novel coronavirus in China: A systematic review
Zhang, L., & Liu, Y. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25707 · Cited by 1,348
Metadata
- Authors
- Loutfy, M. R., Blatt, L. M., Siminovitch, K. A., Ward, S., Wolff, B., Lho, H., Pham, D. H., Deif, H., LaMere, E. A., Chang, M., Kain, K. C., Farcas, G. A., Ferguson, P., Latchford, M., Levy, G., Dennis, J. W., Lai, E. K. Y., & Fish, E. N.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2003-12-24
- Volume
- 290
- Issue
- 24
- Pages
- 3222
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2098728713
- Cited by
- 381
- References
- 11
- FWCI
- 16.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.